Overall, the findings from these two recently completed cardiovascular outcomes trials suggest that the increases in HR associated with the short-acting GLP-1 RA, lixisenatide, or the long-acting GLP-1 RA, liraglutide, do not lead to an increased risk of major adverse cardiac events in patients with T2DM and high cardiovascular risk
Garanta de calidad de VitaOn La confianza de nuestros clientes es una prioridad fundamental
Lutz Schomburg, Charit Universittsmedizin Berlin, Germany Updates Copyright 2023 Wang, Li, Li, Cui, Zhao and Liao
Myth: You can get all the glutathione you need from food
The associations were robust to using the weighted median and weighted mode (Additional file 2: Fig
The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis